Found: 6
Select item for more details and to access through your institution.
Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 1, p. 7, doi. 10.1007/s10637-007-9078-z
- By:
- Publication type:
- Article
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer<sup>?</sup>.
- Published in:
- Oncogene, 2003, v. 22, n. 38, p. 6005, doi. 10.1038/sj.onc.1206797
- By:
- Publication type:
- Article
A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
- Published in:
- Journal of Translational Medicine, 2007, v. 5, p. 61, doi. 10.1186/1479-5876-5-61
- By:
- Publication type:
- Article
Identification of the platelet ADP receptor targeted by antithrombotic drugs.
- Published in:
- Nature, 2001, v. 409, n. 6817, p. 202, doi. 10.1038/35051599
- By:
- Publication type:
- Article
Preclinical evaluation of an anti-α5β1 integrin antibody as a novel anti-angiogenic agent.
- Published in:
- Journal of Experimental Therapeutics & Oncology, 2006, v. 5, n. 4, p. 273
- By:
- Publication type:
- Article
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 5, p. 951, doi. 10.1007/s00280-014-2426-8
- By:
- Publication type:
- Article